Mark Hoenerhoff, DVM, PhD
University of Michigan
Jack Harkema, PhD, DVM
Michigan State University
Session Description: Veterinary toxicologic pathologists play an integral role in biomedical and basic sciences, through translation of preclinical in vivo data for the study of human disease, development of new technologies and medical interventions, and drug development. Toxicologic pathologists also play a role in determination of chemical/drug adversity in animals and humans, and help predict relevance to humans taking into account mechanisms and margin of safety. Working with researchers, clinicians, and toxicologists, toxicologic pathologists can help facilitate a better understanding of disease processes through interpretation of animal models, drug development, and improve translatability of preclinical data in the “bench to bedside” approach to patient care.
Through expanding interdisciplinary collaborations with the human medical field and other disciplines, toxicologic pathologists are central to the “One Health” concept at the intersection of all aspects of health care for humans, animals, and environmental health. This session will showcase the role veterinary toxicologic pathologists play in basic research, investigative pathology, drug development, and imaging modalities to strengthen translatability of animal data to the clinic in collaboration with other scientists. This session will also highlight how toxicologic pathologists can inform on the validity, use, relevance, and power of animal models to study human disease.
|Chair - Welcome and Introductions|
|8:30 AM - 9:15 AM||How Toxicologic Pathologists Can Improve the Translatability and Reproducibility of Animal Models
Thomas Rosol, DVM, PhD, DACVP • Ohio University, College of Osteopathic Medicine
|9:15 AM - 10:00 AM||Innate Lymphoid Cell Mediation of Ozone-induced Non-allergic Asthma
Jack Harkema, DVM, PhD, DACVP • Michigan State University College of Veterinary Medicine
|10:00 AM - 10:45 AM||Animal Models to Support Vaccine Development
Rani Sellers, DVM, PhD, DACVP • Pfizer Inc.
|10:45 AM - 11:30 AM||In-Vivo Imaging to Improve Translatability of Preclinical Research in Drug Development
Martin Guillot, DVM, MSc, PhD • Charles River Laboratories, Montreal
|Questions and Answers|